Adaptimmune Therapeutics plc ADAPY
Set alert
0.02 USD 0.00 -11.54%
At close · Oct 30
0.0205 Day range 0.0284
0.001 52-week range 0.07
- YTD
- -11.54%
- 1 year
- -54.90%
- Open
- 0.0284
- Prev close
- 0.026
- Mkt cap
- 6.10M
- Vol
- 250.91K
- Avg vol
- 187.90K
- EPS
- -0.67
- P/E
- 0.00
More statistics
- Low
- 0.0205
- High
- 0.0284
3M chart
Signals (25)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 3 days ago |
| SMA: Bullish | Oct 27, 2026 | 5 days ago |
| SMA: Bearish | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 26, 2026 | 6 days ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 3, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
Financials — quick view
ADAPY Revenue — quarterly 13.68M
ADAPY Net income — quarterly -30.34M
ADAPY EPS — quarterly -0.12
News
- Adaptimmune Announces Changes to Board and Executive Leadership Team
- AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
- Adaptimmune Announces Delisting from Nasdaq
- Adaptimmune Reports Q2 Financial Results and Provides Business Update
- Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
- Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
- Adaptimmune Reports Q1 Financial Results and Provides Business Update
- Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
- Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
- Adaptimmune Provides Q4 and Full Year 2024 Business Update
Your note
Sign in to keep a note on ADAPY — it syncs with the Stock Master app.